Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

October 11, 2007 updated by: Cortice Biosciences, Inc.

A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies

Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material. The synthesis involves modification to the taxane side chain to overcome multidrug resistance and to achieve mutant tubulin binding. This study will be a multi-center, dose escalation, sequential group, Phase 1 study evaluating the intravenous administration of TPI 287 on an every 21 day cycle.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The primary objective of this study is to determine the maximum tolerated dose of TPI 287 administered every 21 days for Phase II clinical trials.

Study Type

Interventional

Enrollment

45

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Colorado
      • Denver, Colorado, United States, 80218
        • Rocky Mountain Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Patients must be/have:

  • Histological evidence of malignancy
  • Advanced solid tumors that have recurred or progressed following standard therapy
  • Failed one prior therapy or have no standard therapy available
  • Ambulatory with ECOG of 0-1 and estimated life expectancy of > 3 months
  • If female, negative pregnancy test
  • If of childbearing years, agree to use birth control
  • If patient with prior radiation therapy for brain metastases, on steroids, must have been stable for 1 month

Exclusion Criteria:

Patients will be excluded if they are or have had:

  • Prior radiation within 4 weeks
  • Active medical condition or organ disease which may compromise safety or interfere with the study
  • Clinically significant cardiac co-morbidities or pulmonary impairment
  • Concomitant therapy needs
  • Treated with any investigational drugs within 30 days
  • Tumors involve major artery or vein
  • Prior or concurrent central nervous system (CNS) disease
  • Less than 4 weeks since major surgery
  • Known to be positive for HIV, hepatitis B or C
  • Concurrent use of aspirin
  • Use of thrombolytic agents
  • Uncontrolled hypertension
  • Grade II-IV peripheral vascular disease
  • Pregnant or lactating
  • Prior allergic history to compounds of similar chemical composition
  • Inpatients
  • Grade II-IV peripheral neuropathy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
To determine the maximum tolerated dose of TPI 287 administered every 21 days

Secondary Outcome Measures

Outcome Measure
To determine the safety of TPI 287
To determine the antitumor activity of TPI 287
To determine the pharmacokinetic profile of TPI 287

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cortice Biosciences, Inc.

Investigators

  • Study Director: Sandra Silberman, MD, Tapestry Pharmaceuticals, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2005

Study Completion (Actual)

February 1, 2007

Study Registration Dates

First Submitted

November 16, 2005

First Submitted That Met QC Criteria

November 16, 2005

First Posted (Estimate)

November 21, 2005

Study Record Updates

Last Update Posted (Estimate)

October 15, 2007

Last Update Submitted That Met QC Criteria

October 11, 2007

Last Verified

November 1, 2005

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TPI 287-02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoplasms

Clinical Trials on TPI 287 Injection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe